Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death, and no effective therapy is currently available for it. We have identified a previously undescribed role of mast cells in PDAC. Mast cells migrate to the tumor site and provide a microenvironment that allows for tumor progression. These results highlight the practical importance of mast cells in PDAC and indicate that targeting mast cells may be a promising novel therapy for PDAC. Research.
STATEMENT OF TRANSLATIONAL RELEVANCE
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death, and no effective therapy is currently available for it. We have identified a previously 
Introduction
Pancreatic ductal adenocarcinoma (PDAC), whose nomenclature derives from its histologic resemblance to ductal cells, is the most common pancreatic malignancy, and an estimated 213,000 new cases are diagnosed worldwide annually (1) . It is the fourthleading cause of cancer death in the United States, with very dismal survival rates.
Median survival duration after diagnosis is 3-6 months and the 5-year survival rate is less than 5%, which is the lowest survival rate of all cancer types (1) . Moreover, this cancer is notoriously resistant to all conventional treatment modalities, including chemotherapy, radiotherapy, and even modern targeted therapies. The lack of effective treatment results from a poor understanding of PDAC tumor biology. Therefore, a better understanding of PDAC's aggressive characteristics and tumorigenesis is needed before treatment advances can be made.
Recently, inflammation and other tumor microenvironment characteristics have drawn attention as central factors in the tumorigenesis of many cancers. The association between inflammation and PDAC development has been known for years (2, 3) and was recently validated in an animal model (4) . Throughout the process of tumorigenesis, disease progression, and metastasis, the microenvironment of the local host tissue is an active participant and determines the extent of cancer cell proliferation, angiogenesis, invasion, and survival (5, 6) . Treatments that target both the cancer and its surrounding microenvironment may provide the best approach (7, 8) . This approach is particularly useful in PDAC, which is characterized by a dense tumor stroma that contains a cell-rich (8) .
The presence of these immune regulatory cells in the tumor stroma contributes significantly to the immunosuppressive microenvironment (9) that promotes tumorigenesis.
One type of these inflammatory cells, mast cells, has begun to receive attention for its role in human malignancy. Mast cells regulate adaptive immune responses via the release of cytokines and other immunomodulatory factors (10) (11) (12) . These factors can promote immune suppression and may contribute to PDAC progression. The important roles of mast cells have been reported in many human malignancies (13) (14) (15) (16) (17) . However, the role of mast cells in human PDAC remains obscure.
We hypothesize that mast cells in the tumor microenvironment are essential for PDAC tumorigenesis. To test this hypothesis, we employed a transgenic spontaneous PDAC mouse model and observed an early influx of mast cells to the tumor microenvironment, which suggests that mast cells in the tumor microenvironment are essential for PDAC tumorigenesis. We investigated the contribution of mast cells to PDAC tumorigenesis by using a mast cell-deficient mouse model (Kit 
Materials and Methods

Mouse models
K-Ras G12V mutation mice were developed by our group (4) . The K-Ras G12V knockin mice have been described previously (4) . Briefly, K-Ras Animal Care and Use Committee approved all the animal procedures described here (4, 19) .
Immunohistochemical and histochemical staining with image analysis
Immunohistochemical studies were performed using markers for inflammatory cells, 
Orthotopic PDAC mouse models
To perform the intrapancreatic injection, we anesthetized mice with 2.5% tribromoethanol and made a 0.5-1-cm incision in the left subcostal region. Panc-02 PDAC tumor cells were injected into the caudal pancreas (20) . The peritoneum and skin were closed with the EZ Clip wound-closing kit (Stoelting Co.). At 2 weeks after implantation, five mice from each group were euthanized every 7 days, and PDAC tumors were evaluated macroscopically for the presence of orthotopic tumors and metastases in the abdominal cavity (20) . Tumor volumes were estimated using the following formula: (π × long axis × short axis × short axis) ÷ 6 (21) . An additional 40 mice in each group were used for survival analysis. Archival tissue blocks and their matching hematoxylin and eosin-stained slides were retrieved, reviewed, and screened by a gastrointestinal pathologist (H. W.) to identify representative tumor regions and non-neoplastic pancreatic parenchyma. For each patient, two cores of tumor tissue and two cores of paired benign pancreatic tissue were sampled from representative areas using a 1.0-mm punch. The tissue microarrays were constructed with a tissue microarrayer (Beecher Instruments, Sun Prairie, WI) as described previously (22) . The cutoff point of the mast cell score was 3.68 (i.e., 75th percentile of the mast cell score in the sample population.
Patients and tissue samples
Statistical analysis
Student's t-tests and one-way analysis of variance were used to compare quantification data. Survival probability curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of differences. 
Statistical analysis was performed using Statistical Package for Social Sciences software (SPSS Inc.). We used a two-sided significance level of 0.05 for all statistical analyses. (Figure 4 a, d, g ), and as expected, no mast cells were found in the pancreases of Kit-/-mice (Figure 4 b, e, h) . Similar results were observed in a subcutaneous model with Panc-02 cells (data not shown).
Results
Mast
To further confirm the hypothesis that mast cells promote PDAC tumorigenesis, we employed a mast cell reconstitution mouse model. Bone marrow-derived mast cells from WT C56BL/6 mice were injected into mast cell-deficient Kit 
. Mast cell reconstitution also increased the incidence of hemorrhagic ascites to 50%.
The repopulation of mast cells was confirmed by both hematoxylin and eosin and toluidine blue staining (Figure 4 c, f, i) . These data support the critical role of mast cells in PDAC progression.
Mast cells infiltration predicts a worse prognosis of patients with PDAC
To determine the clinical relevance of mast cell influx in PDAC, we stained 67 pancreaticoduodenectomy specimens from a previously constructed tissue microarray with toluidine blue and counted the mast cells (Figure 5 a-e) . Patients with mast cell scores < 3.68 survived significantly longer (median overall survival duration, 36.2 ± 9.4 months) than did patients with mast cell scores ≥ 3.68 (median overall survival duration, 13.4 ± 3.4 months; P = 0.008, high vs. low mast cell infiltration) (Figure 5 f) . In addition, the incidence of recurrence was lower in patients with mast cell scores < 3.68 (67%) than in patients with mast cell scores ≥ 3.68 (100%; P =0.003, Fisher's exact test.). In multivariate analysis (Supplemental Table) , master cell score is close to, but does not reach statistical significance (hazard ratio: 1.88, 95% confidence interval: 0.95-3.73, p=0.07) after adjusting lymph node status. The lymph node metastasis is an independent prognostic factors for poor survival (hazard ratio: 2.31, 95% confidence interval: 1.10- Mast cells are important in allergic and late-phase reactions, inflammation, and the regulation of adaptive T-cell-mediated immunity (23) (24) (25) . However, the role of mast cells in the tumorigenesis of cancers is not totally clearly, and data regarding their benefit or detriment to tumorigenesis have been controversial, depending on the local stromal conditions (26) . On the one hand, mast cells may promote tumor development by (1) facilitating tumor angiogenesis through heparin-like molecules, and heparin could further permit neovascularization and metastasis through its anti-clotting effects (27) ; (2) secreting histamine and growth factors, such as vascular endothelial growth factor, platelet-derived growth factor, stem cell factor, and nerve growth factor, which may facilitate the proliferation of tumor cells, and (3) contributing proteolytic components necessary for tumor invasiveness (28) . On the other hand, mast cells could also be detrimental to tumor growth by secreting several cytokines, such as IL-4, and proteolytic enzymes that may induce the apoptosis of malignant cells (29) . Consistent with the dual 
roles of mast cells in inhibiting or promoting tumor growth, high mast cell numbers represent a good prognostic indicator in breast cancer, non-small cell lung carcinoma, and ovarian cancer (16, 17) , but they are associated with poor prognosis in skin cancer (both melanoma and non-melanoma and Merkel cell tumors) (13, 14) , oral squamous cell carcinoma, several types of lymphoma, and prostate cancer (16, 17) .
Inflammation is associated with an increased risk for most cancers. CP produces pancreatic inflammation and is associated with an increased risk of PDAC, thus establishing a link between cancer and inflammation on an epidemiological level (2, 3).
To determine the role of mast cells in PDAC tumorigenesis, we first determined when and how much mast cells infiltrate the PDAC tumor microenvironment, using a K-ras G12V transgenic spontaneous mouse model (4). Activating K-RAS point mutations at codon 12 (from GGT to GAT or GTT, and more rarely, CGT) results in the substitution of glycine with aspartate, valine, or arginine. These mutations are the first known genetic alterations in PDAC, occurring sporadically in normal pancreatic tissue, and are detected in ∼30% of early neoplasms, with the frequency rising to nearly 100% in advanced PDAC (32, 33) . PDACs nearly always arise from precursors that sustain activating K-RAS mutations, whereas such mutations are almost never seen in less common pancreatic cancers such as islet cell carcinomas (34, 35) . Thus, the PDAC generated in this mouse 
